This interview provides insights into the current disease landscape for NASH, including experience with prescribing the first US approved drug, Madrigal Pharmaceuticals’ Rezdiffra, and expectations for late-phase pipeline therapies with a focus on incretins, FGF21 analogs, and THR-beta agonists. Key assets highlighted include Novo Nordisk’s semaglutide, Inventiva Pharma’s lanifibranor, Akero Therapeutics’ efruxifermin, 89bio’s pegozafermin, Eli Lilly’s tirzepatide, and Boehringer Ingelheim’s survodutide. 

This interview was conducted on 6 June 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.